Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : ADVR:THE NEW COMPANY...WITH A NEW LIFE...AND A NEW MISSION -- Ignore unavailable to you. Want to Upgrade?

To: KAKALAK who wrote (4735)	1/27/2000 8:51:00 PM
From: will tra	Respond to of 4891

That really sounds great. Are the sources official or just hearsay? If official, would you mind sharing them with us? We're long on this stock for a long long time & would love to see a breakthrough. No product- no profit.

To: KAKALAK who wrote (4735)	1/27/2000 9:48:00 PM
From: Kingfisher	Read Replies (1) \| Respond to of 4891

The following message was posted on the CNBC ADVR message board on 1/25/00. ADVR's product has already been approved by Mercosur ( the South American equivalent of the F.D.A.) for use within the region not only for enhancing the aids cocktail but also for use with a variety of other virus, such as various forms of Cancer. Once approved by the F.D.A. and distribution begins in the States it is anticipated that it will be a $8.00 to $12.00 stock when approved by the F.D.A. and $80.00 to $100.00 within the first 12 to 18 months of distribution. First, Mercosur is not the South American equivalent of the FDA. It is a trade organization consisting of Latin American countries. Second, the organization that would be approving Reticulose or Substance R is ANMAT, the Argentine equivalent of the FDA. It is true that if Reticulose or Substance R were approved by ANMAT, ADVR would have approval to sell the drug in the other Mercosur countries. However, since the Gold Eagle seems to have the facts wrong, chances are the above post is a bunch of bull. It would be great news if this were true but I am highly sceptical. Also, does anyone know who this geoman88 is? Claims he has been in ADVR stock for 4 1/2 years and he spells Reticulose - "retilouse", admitting he is unsure of the spelling. If you think about it, that isn't even close. One should do a little research on a company before investing their money and should be fairly well familiar with their product at least to the point of knowing how to spell the product.